[YOON, Jae Bong 윤재봉, YOON, Jae Bong 윤재봉, YOO, Jinsang 유진상, YOON, Jae Bong 윤재봉, YOO, Jinsang 유진상, YOO, Jin San 유진산, YOON, Jae Bong 윤재봉, YOO, Jinsang 유진상, YOO, Jin San 유진산, LEE, Weon Sup 이원섭, YOON, Jae Bong 윤재봉, YOO, Jinsang 유진상, YOO, Jin San 유진산, LEE, Weon Sup 이원섭, KIM, Sung-Woo 김성우, YOON, Jae Bong 윤재봉, YOO, Jinsang 유진상, YOO, Jin San 유진산, LEE, Weon Sup 이원섭, KIM, Sung-Woo 김성우, SHIM, Sang Ryeol 심상렬, YOON, Jae Bong 윤재봉, YOO, Jinsang 유진상, YOO, Jin San 유진산, LEE, Weon Sup 이원섭, KIM, Sung-Woo 김성우, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, YOON, Jae Bong 윤재봉, YOO, Jinsang 유진상, YOO, Jin San 유진산, LEE, Weon Sup 이원섭, KIM, Sung-Woo 김성우, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, LEE, Youngae 이영애, YOON, Jae Bong 윤재봉, YOO, Jinsang 유진상, YOO, Jin San 유진산, LEE, Weon Sup 이원섭, KIM, Sung-Woo 김성우, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, LEE, Youngae 이영애, LEE, Hyuk Joon 이혁준, YOON, Jae Bong 윤재봉, YOO, Jinsang 유진상, YOO, Jin San 유진산, LEE, Weon Sup 이원섭, KIM, Sung-Woo 김성우, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, LEE, Youngae 이영애, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, YOON, Jae Bong 윤재봉, YOO, Jinsang 유진상, YOO, Jin San 유진산, LEE, Weon Sup 이원섭, KIM, Sung-Woo 김성우, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, LEE, Youngae 이영애, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, CHOI, Jinhee 최진희] No. 307 34112 대전광역시 유성구 대덕대로 593, 307호, Daejeon593, Daedeok-daeroYuseong-guDaejeon 34112 The present invention relates to an antibody that specifically binds to epidermal growth factor receptor variant III (EGFRvIII), a nucleic acid encoding the antibody, a vector and a host cell comprising the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumors, comprising the antibody as an active ingredient.

[YOO, Jinsang 유진상, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, LEE, Hyuk Joon 이혁준, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, KIM, Yeon Ju 김연주, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, KIM, Yeon Ju 김연주, JEON, Mi Ae 전미애, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, KIM, Yeon Ju 김연주, JEON, Mi Ae 전미애, CHOI, Jinhee 최진희, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, KIM, Yeon Ju 김연주, JEON, Mi Ae 전미애, CHOI, Jinhee 최진희, LEE, Youngae 이영애, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, KIM, Yeon Ju 김연주, JEON, Mi Ae 전미애, CHOI, Jinhee 최진희, LEE, Youngae 이영애, NAHM, Kyoung Hee 남경희, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, KIM, Yeon Ju 김연주, JEON, Mi Ae 전미애, CHOI, Jinhee 최진희, LEE, Youngae 이영애, NAHM, Kyoung Hee 남경희, JEONG, Boyoung 정보영, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, KIM, Yeon Ju 김연주, JEON, Mi Ae 전미애, CHOI, Jinhee 최진희, LEE, Youngae 이영애, NAHM, Kyoung Hee 남경희, JEONG, Boyoung 정보영, LEE, Seon Young 이선영, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, KIM, Yeon Ju 김연주, JEON, Mi Ae 전미애, CHOI, Jinhee 최진희, LEE, Youngae 이영애, NAHM, Kyoung Hee 남경희, JEONG, Boyoung 정보영, LEE, Seon Young 이선영, JEONG, Jong Geun 정종근, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, KIM, Yeon Ju 김연주, JEON, Mi Ae 전미애, CHOI, Jinhee 최진희, LEE, Youngae 이영애, NAHM, Kyoung Hee 남경희, JEONG, Boyoung 정보영, LEE, Seon Young 이선영, JEONG, Jong Geun 정종근, YOON, Jae Bong 윤재봉, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, KIM, Yeon Ju 김연주, JEON, Mi Ae 전미애, CHOI, Jinhee 최진희, LEE, Youngae 이영애, NAHM, Kyoung Hee 남경희, JEONG, Boyoung 정보영, LEE, Seon Young 이선영, JEONG, Jong Geun 정종근, YOON, Jae Bong 윤재봉, KIM, Nam Ye 김남예, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, KIM, Yeon Ju 김연주, JEON, Mi Ae 전미애, CHOI, Jinhee 최진희, LEE, Youngae 이영애, NAHM, Kyoung Hee 남경희, JEONG, Boyoung 정보영, LEE, Seon Young 이선영, JEONG, Jong Geun 정종근, YOON, Jae Bong 윤재봉, KIM, Nam Ye 김남예, OH, Seon Hwan 오선환, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, KIM, Yeon Ju 김연주, JEON, Mi Ae 전미애, CHOI, Jinhee 최진희, LEE, Youngae 이영애, NAHM, Kyoung Hee 남경희, JEONG, Boyoung 정보영, LEE, Seon Young 이선영, JEONG, Jong Geun 정종근, YOON, Jae Bong 윤재봉, KIM, Nam Ye 김남예, OH, Seon Hwan 오선환, LEE, Eun Hee 이은희, YOO, Jinsang 유진상, NAM, Ju Ryoung 남주령, YOO, Jin San 유진산, KIM, Sung-Woo 김성우, LEE, Weon Sup 이원섭, SHIM, Sang Ryeol 심상렬, BYUN, Sang Soon 변상순, PARK, Miju 박미주, LEE, Hyuk Joon 이혁준, KIM, Do Yun 김도윤, KIM, Yeon Ju 김연주, JEON, Mi Ae 전미애, CHOI, Jinhee 최진희, LEE, Youngae 이영애, NAHM, Kyoung Hee 남경희, JEONG, Boyoung 정보영, LEE, Seon Young 이선영, JEONG, Jong Geun 정종근, YOON, Jae Bong 윤재봉, KIM, Nam Ye 김남예, OH, Seon Hwan 오선환, LEE, Eun Hee 이은희, JEONG, Ji Hye 정지혜] No. 307 34112 대전시 유성구 대덕대로 593, 307호, Daejeon593, Daedeok-daeroYuseong-guDaejeon 34112 The present invention relates to an antibody and a fragment thereof which specifically bind to c-Met and, more specifically, to a complete human antibody having high affinity and specificity to c-Met isolated from a human Fv (ScFv) phage library, and to a method for preparing a polynucleotide coding the antibody, a recombinant vector containing the polynucleotide, a cell transformed with the recombinant vector, and an antibody specific to c-Met by incubating the cell. The antibody specific to c-Met according to the present invention can efficiently control the activity of c-Met in vivo.

[KIM, Hyo-Soo 김효수, JANG, Hyun-Duk 장현덕, PARK, Bum-Chan 박범찬, YOON, Jae Bong 윤재봉, PARK, Jae Eun 박재은, YANG, So Young 양소영, JEON, Eun Young 전은영, KIM, Soo Young 김수영, LEE, Ji Su 이지수, LEE, Jae Min 이재민, LEE, Dong Jung 이동중, SONG, Ji Ahn 송지안] 101 Daehak-ro 03080 서울특별시 종로구 대학료 101, SeoulJongno-guSeoul 03080;3F., 29 Techno 4-ro 34014 대전광역시 유성구 테크노4로 29 3층, DaejeonYuseong-guDaejeon 34014 The present invention relates to an antibody against resistin and use thereof and, more specifically, to a resistin antibody or antigen-binding fragment thereof that inhibits the activity of resistin by blocking resistin/CAP1 binding, a nucleic acid encoding same, a vector comprising the nucleic acid, a cell transformed with the vector, a method for preparing the antibody or antigen-binding fragment thereof, an antibody-drug conjugate comprising the antibody or antigen-binding fragment thereof, a bi- or multi-specific antibody, a chimeric antigen receptor, an immune cell containing same, and a composition for the prevention or treatment of diseases that can be treated through the inhibition of resistin activity, the composition comprising same. A novel antibody or antigen-binding fragment thereof that binds to resistin, according to the present invention, blocks resistin/CAP1 binding by binding to resistin, thereby inhibiting the activity of resistin, and thus is useful for the development of therapeutic agents for various diseases associated with resistin.

[YOON, Jae Bong 윤재봉, JEON, Eun Young 전은영, YOO, Seok Ho 유석호, PARK, Jae Eun 박재은, KANG, Won Hwa 강원화, KIM, Hye-Nan 김혜난, KIM, Yeung Chul 김응철, KIM, Soo Young 김수영, LIM, Jury 임주리, CHO, Young-Gyu 조영규, PARK, Bum-Chan 박범찬, LIM, Jung Chae 임정채, PARK, Young Woo 박영우] 3F. 34014 대전시 유성구 테크노4로 29 3층, Daejeon29, Techno 4-roYuseong-guDaejeon 34014 The present invention relates to an antibody binding specifically to IL-17A or an antigen-binding fragment thereof, a polynucleotide coding therefor, a vector carrying the polynucleotide, a cell transformed with the vector, a method for preparing the antibody or an antigen-binding fragment thereof, an antibody-drug conjugate comprising the antibody or an antigen-binding fragment thereof, a diabody comprising the antibody or an antigen-binding fragment thereof, and a composition thereof for prevention or treatment of cancer or autoimmune diseases.

[YOON, Jae Bong 윤재봉, JEON, Eun Young 전은영, LEE, Jin Sil 이진실, BAEK, Gi Sun 백기선, YOO, Seok Ho 유석호, LIM, Jung Chae 임정채, PARK, Bum-Chan 박범찬, CHO, Young-Gyu 조영규, PARK, Young Woo 박영우] 3F. 34014 대전시 유성구 테크노4로 29 3층, Daejeon29, Techno 4-roYuseong-guDaejeon 34014 The present invention relates to a bispecific antibody specifically binding to IL-17A and TNF-α, and uses thereof. The bispecific antibody or an antigen binding fragment thereof, according to the present invention, exhibits high specificity with respect to IL-17A and TNF-α and an excellent neutralization ability compared to a conventional monospecific antibody, while quickly inhibiting inflammation and an immune reaction by inhibiting IL-17 and TNF-α at the same time, and, thereby, has the benefit of improving a treatment effect and decreasing an administration amount. The present invention relates to a bispecific antibody specifically binding to IL-17A and TNF-α, and uses thereof. The bispecific antibody or an antigen binding fragment thereof, according to the present invention, exhibits high specificity with respect to IL-17A and TNF-α and an excellent neutralization ability compared to a conventional monospecific antibody, while quickly inhibiting inflammation and an immune reaction by inhibiting IL-17 and TNF-α at the same time, and, thereby, has the benefit of improving a treatment effect and decreasing an administration amount.

[YOON, Jae Bong 윤재봉, LIM, Hye Lim 임혜림, CHEON, Seong Hye 천성혜, LEE, Song Ha 이송하, JEON, Eun Young 전은영, KIM, Sung Il 김성일, LEE, Sang Heon 이상헌, LEE, Han Seung 이한승, JANG, Woo Ick 장우익] 3F, 29 Techno 4-ro, 34014 대전광역시 유성구 테크노4로 29, 3층, DaejeonYuseong-guDaejeon 34014 An antibody of the present invention that specifically binds to PD-1, or an antigen-binding fragment of the antibody, can inhibit the activity of PD-1, for example by binding to PD-1 and inhibiting the interaction between PD-1 and PD-L1, and is thus useful in developing immunotherapeutic agents for various neuroendocrine neoplasms.